Cytomel (Liothyronine) Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

How Liothyronine Works at the Molecular Level

Liothyronine is the pharmaceutical name for synthetic triiodothyronine, the biologically active thyroid hormone. Unlike levothyroxine (T4), which requires conversion by type 1 and type 2 deiodinase enzymes before acting on tissues, liothyronine binds directly to nuclear thyroid hormone receptors (THR-alpha and THR-beta) without any activation step [1].

This direct action is why clinicians sometimes add T3 to a T4 regimen. T3 binds THR-beta with an affinity approximately 10 to 15 times higher than T4 does [2]. Once bound, the T3-receptor complex recruits coactivator proteins and binds thyroid response elements on DNA, modulating transcription of genes that govern basal metabolic rate, cardiac contractility, thermogenesis, and neuronal development [3]. The Bunevicius et al. trial (N=33) published in the New England Journal of Medicine demonstrated that substituting 12.5 mcg of liothyronine for 50 mcg of levothyroxine improved mood scores and neuropsychological performance in hypothyroid patients, suggesting that some individuals may rely on exogenous T3 when peripheral conversion is insufficient [4].

A single 25 mcg oral dose can raise serum free T3 by 50 to 100% above baseline within 2 to 4 hours, then decay over 24 to 48 hours following first-order elimination kinetics [5]. This sharp pharmacokinetic profile creates both clinical advantages (rapid symptom relief) and challenges (peak-related side effects such as palpitations and dosing complexity). The FDA-approved prescribing information for Cytomel notes that its metabolic effects begin within a few hours and dissipate over 1 to 2 days [6].

Absorption: Near-Complete Uptake from the GI Tract

Liothyronine is absorbed almost entirely from the jejunum and upper ileum, with oral bioavailability estimated at approximately 95%. This contrasts with levothyroxine, whose bioavailability ranges from 40 to 80% depending on formulation and fasting state [7].

Peak serum concentrations occur 2 to 4 hours after ingestion on an empty stomach. Food delays absorption modestly but does not significantly reduce total drug exposure. The American Thyroid Association (ATA) guidelines recommend consistent timing relative to meals when T3 is used adjunctively [8]. Calcium supplements, iron salts, and proton pump inhibitors can interfere with T4 absorption, but the evidence for clinically meaningful interference with T3 absorption is limited because T3's near-complete bioavailability leaves little room for reduction [9].

Gastric pH does not substantially alter liothyronine uptake. Patients with achlorhydria or those taking omeprazole show preserved T3 absorption, a point that distinguishes liothyronine from levothyroxine in patients with upper GI comorbidities [7]. One pharmacokinetic study in healthy volunteers found that the area under the curve (AUC) for a 50 mcg liothyronine dose was 98.3% of the IV reference, confirming that first-pass hepatic extraction is negligible for T3 at therapeutic doses [5].

Distribution: Protein Binding and Tissue Penetration

Once absorbed, liothyronine distributes rapidly into a volume of approximately 40 to 50 liters. It is greater than 99% bound to three plasma proteins. Thyroxine-binding globulin (TBG) carries the majority, with albumin and transthyretin (formerly called thyroxine-binding prealbumin) accounting for the remainder [10].

Only the free (unbound) fraction, roughly 0.3% of total serum T3, is biologically active. This means that conditions altering TBG concentration change total T3 measurements without necessarily affecting free T3 or clinical thyroid status. Pregnancy, oral estrogen use, and hepatitis increase TBG and raise total T3; nephrotic syndrome, androgens, and severe illness decrease TBG and lower total T3 [10]. Clinicians monitoring patients on liothyronine should rely on free T3 assays rather than total T3 to avoid misinterpretation [11].

T3 crosses the blood-brain barrier via monocarboxylate transporter 8 (MCT8) and organic anion transporting polypeptide 1C1 (OATP1C1). Mutations in MCT8 cause Allan-Herndon-Dudley syndrome, characterized by severe psychomotor disability despite elevated serum T3, confirming that transporter-mediated uptake is required for central nervous system T3 action [12]. In peripheral tissues, T3 enters cells through MCT8 and MCT10, concentrating in the liver, kidneys, heart, and skeletal muscle within 4 to 6 hours of dosing [13].

The Endocrine Society's 2012 clinical practice guideline noted: "Serum T3 concentrations after oral liothyronine exhibit a peak-to-trough variation that does not mimic the relatively stable T3 levels produced by peripheral T4-to-T3 conversion" [14]. This pharmacokinetic reality drives interest in sustained-release T3 formulations.

Metabolism: Deiodination and Hepatic Conjugation

Liothyronine undergoes two primary metabolic processes. The dominant pathway is sequential deiodination: removal of iodine atoms by deiodinase enzymes (D1, D2, D3) converts T3 first to 3,5-diiodothyronine (T2) and then to monoiodothyronine (T1) [15]. These lower iodothyronines were traditionally considered inactive metabolites, though emerging evidence suggests T2 may have independent effects on mitochondrial respiration and lipid metabolism [16].

The second pathway is hepatic conjugation. In hepatocytes, T3 undergoes glucuronidation by UDP-glucuronosyltransferases and sulfation by sulfotransferases (primarily SULT1A1 and SULT1A3). Glucuronidated T3 is excreted into bile, where intestinal bacteria can hydrolyze the conjugate and release free T3 for reabsorption, establishing an enterohepatic circulation that partially extends T3's biological duration [15].

Drugs that induce hepatic conjugation enzymes accelerate T3 clearance. Phenobarbital, phenytoin, carbamazepine, and rifampin all increase T3 metabolic clearance rate by 20 to 50%, potentially necessitating dose adjustments in patients on anticonvulsant therapy [8]. A study by Sapin et al. found that carbamazepine reduced free T3 levels by approximately 25% in euthyroid epilepsy patients, a clinically relevant interaction for those also taking exogenous liothyronine [17].

Dr. Antonio Bianco, a thyroid hormone metabolism researcher at the University of Chicago, has stated: "The deiodinase system acts as a gatekeeper, locally controlling how much active T3 reaches the nucleus of each cell. When you give exogenous T3, you bypass that gate entirely, which is why pharmacokinetics matter so much for dosing strategy" [18].

Excretion: Renal Elimination and Enterohepatic Recycling

The plasma elimination half-life of liothyronine is approximately 1 to 2 days in euthyroid adults, a value confirmed by multiple single-dose pharmacokinetic studies using radiolabeled T3 [5]. This is substantially shorter than levothyroxine's 6 to 7 day half-life, which is why T3 requires more frequent dosing for stable serum levels.

Approximately 80% of an administered T3 dose is ultimately excreted through the kidneys as deiodinated and conjugated metabolites. The remaining 20% is eliminated via fecal excretion of biliary conjugates that escape enterohepatic reabsorption [15]. In patients with moderate renal impairment (eGFR 30 to 59 mL/min), T3 clearance decreases modestly, but dose adjustments are not routinely required because the therapeutic window is monitored by serum free T3 and TSH rather than by pharmacokinetic calculations [6].

Hepatic impairment affects T3 elimination more meaningfully. Patients with Child-Pugh class B or C cirrhosis show reduced conjugation capacity, which can prolong T3's effective half-life and increase the risk of supraphysiological exposure [11]. TBG synthesis also falls in cirrhosis, compounding the issue by raising the free T3 fraction relative to total T3.

In hyperthyroid states (whether iatrogenic from excessive dosing or endogenous), the metabolic clearance rate of T3 paradoxically increases because thyroid hormones upregulate their own deiodinase and conjugation pathways. This means that a patient who becomes mildly thyrotoxic on liothyronine will clear the excess T3 faster than predicted by euthyroid pharmacokinetic data, an inherent safety buffer [15].

Clinical Implications of Liothyronine's PK Profile

The rapid absorption and short half-life of liothyronine have three practical consequences for prescribers. First, once-daily dosing produces peak-to-trough serum T3 swings of 40 to 100%, depending on the dose. Split dosing (e.g., 5 mcg twice daily instead of 10 mcg once daily) flattens these excursions and may reduce peak-related symptoms such as tachycardia, anxiety, and tremor [19].

Second, the timing of blood draws matters. TSH and free T3 measured 4 hours post-dose will capture the T3 peak. The ATA recommends measuring thyroid function tests at least 8 to 12 hours after the last liothyronine dose, or ideally, before the morning dose [8]. Drawing labs at the peak inflates the free T3 reading and can prompt unnecessary dose reductions.

Third, the 1 to 2 day half-life means that steady-state serum levels are achieved within approximately 5 to 7 days of initiating or changing a dose. This is far faster than the 5 to 6 weeks required to reach steady state on levothyroxine. Clinicians can reassess TSH as early as 2 weeks after a liothyronine dose change, though a 4 to 6 week interval remains standard practice for TSH stabilization [8].

A 2004 pharmacokinetic modeling study by Jonklaas et al. (N=12) evaluated slow-release triiodothyronine and found that a formulation releasing T3 over 8 to 12 hours reduced Cmax by 36% compared to immediate-release Cytomel while maintaining equivalent AUC [20]. Such data support the clinical rationale for sustained-release T3 development, though no slow-release T3 product has received FDA approval as of May 2026.

Special Populations: How PK Parameters Shift

Elderly patients (age >65) show a 10 to 15% reduction in T3 metabolic clearance rate compared to younger adults, attributable to decreased hepatic blood flow and reduced deiodinase activity [21]. Starting doses in older adults should be 5 mcg daily or lower, with cautious titration.

Pregnancy increases TBG concentrations 2 to 3 fold by the second trimester, raising total T3 without proportionally increasing free T3. The placenta expresses high levels of type 3 deiodinase (D3), which inactivates T3 to reverse T3 (rT3), protecting the fetus from excessive thyroid hormone exposure [22]. Liothyronine is classified as FDA pregnancy category A, though T4 monotherapy remains the standard of care in pregnancy because of T3's pharmacokinetic variability [6].

In critically ill patients, the "nonthyroidal illness syndrome" (also called euthyroid sick syndrome or low-T3 syndrome) reduces peripheral T4-to-T3 conversion and shifts deiodination toward rT3 production. Serum T3 may fall by 40 to 70% during acute illness [23]. Whether exogenous T3 supplementation benefits these patients remains debated; the THYROID-ICU trial is investigating this question in septic shock.

Pediatric patients metabolize T3 faster than adults. Children aged 1 to 3 years have a T3 metabolic clearance rate roughly 50% higher per kilogram of body weight, requiring proportionally larger weight-based doses [24]. Monitoring should occur every 1 to 2 months during the first year of therapy.

Drug Interactions That Alter Liothyronine Pharmacokinetics

Amiodarone is a potent inhibitor of type 1 and type 2 deiodinase due to its high iodine content (37% by weight). In patients receiving both amiodarone and liothyronine, peripheral T3 generation from T4 drops, but the clearance of exogenous T3 may also be altered because amiodarone inhibits the deiodination step that inactivates T3 [25]. This creates a complex pharmacokinetic interaction requiring more frequent monitoring.

Oral estrogens (but not transdermal) increase TBG synthesis, raising total T3 measurements by 20 to 35% without changing free T3 levels. The Endocrine Society guidelines recommend re-checking free T3 and TSH 6 to 8 weeks after initiating or discontinuing oral estrogen therapy in patients on liothyronine [2].

Propranolol at doses of 160 mg/day or higher inhibits type 1 deiodinase, reducing peripheral T4-to-T3 conversion by approximately 20%. For patients on T3 monotherapy, this interaction is less relevant. But in patients taking combination T4/T3, propranolol may shift the balance toward the exogenous T3 component [26].

Warfarin clearance increases in hyperthyroid states because thyroid hormones upregulate vitamin K-dependent clotting factor catabolism. When initiating liothyronine in a patient on warfarin, the INR should be monitored weekly for the first month, as T3's rapid onset can shift anticoagulation status within 48 to 72 hours [6].